TVRD

SEC source: 0001209191-21-018652 · doc4.xml · nonDerivative · entry 2

Terrillion Scott · CIK 0001706426 · Sec'y; Chief Compliance & G.C.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 51,342

F2 · kind: This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person in accordance with Rule 10b5-1 on September 6, 2018 to satisfy the tax withholding obligations triggered by the vesting of RSUs, and does not represent a discretionary trade by the Reporting Person.

SEC source: 0001209191-21-018656 · doc4.xml · nonDerivative · entry 2

Menzaghi Frederique Ph.D. · CIK 0001597152 · Chief Scientific Off,SVP-R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 119,319

F2 · kind: This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person in accordance with Rule 10b5-1 on September 6, 2018 to satisfy the tax withholding obligations triggered by the vesting of RSUs, and does not represent a discretionary trade by the Reporting Person.

SEC source: 0001209191-21-018644 · doc4.xml · nonDerivative · entry 1

CHALMERS DEREK T · CIK 0001166287 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 953,614

F1 · shares: Represents the number of shares that vested under a performance-based restricted stock unit award (the "RSU") based on the Issuer's satisfaction of certain performance criteria of the award. In light of the performance-based vesting conditions of the award, such shares were not reportable under Section 16 until vesting was determined, which occurred on March 4, 2021. Each RSU represents the contingent right to receive one share of common stock of the Issuer.

SEC source: 0001209191-21-018646 · doc4.xml · nonDerivative · entry 1

Goncalves Joana · CIK 0001756991 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,703

F1 · shares: Represents the number of shares that vested under a performance-based restricted stock unit award (the "RSU") based on the Issuer's satisfaction of certain performance criteria of the award. In light of the performance-based vesting conditions of the award, such shares were not reportable under Section 16 until vesting was determined, which occurred on March 4, 2021. Each RSU represents the contingent right to receive one share of common stock of the Issuer.

SEC source: 0001209191-21-018652 · doc4.xml · nonDerivative · entry 1

Terrillion Scott · CIK 0001706426 · Sec'y; Chief Compliance & G.C.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 54,432

F1 · shares: Represents the number of shares that vested under a performance-based restricted stock unit award (the "RSU") based on the Issuer's satisfaction of certain performance criteria of the award. In light of the performance-based vesting conditions of the award, such shares were not reportable under Section 16 until vesting was determined, which occurred on March 4, 2021. Each RSU represents the contingent right to receive one share of common stock of the Issuer.

SEC source: 0001209191-21-018656 · doc4.xml · nonDerivative · entry 1

Menzaghi Frederique Ph.D. · CIK 0001597152 · Chief Scientific Off,SVP-R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 122,677

F1 · shares: Represents the number of shares that vested under a performance-based restricted stock unit award (the "RSU") based on the Issuer's satisfaction of certain performance criteria of the award. In light of the performance-based vesting conditions of the award, such shares were not reportable under Section 16 until vesting was determined, which occurred on March 4, 2021. Each RSU represents the contingent right to receive one share of common stock of the Issuer.

SEC source: 0001209191-21-014547 · doc4.xml · nonDerivative · entry 2

CHALMERS DEREK T · CIK 0001166287 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 943,614

F2 · kind: This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person in accordance with Rule 10b5-1 on September 6, 2018 to satisfy the tax withholding obligations triggered by the vesting of RSUs, and does not represent a discretionary trade by the Reporting Person.

SEC source: 0001209191-21-014548 · doc4.xml · nonDerivative · entry 2

Goncalves Joana · CIK 0001756991 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,703

F2 · kind: This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person in accordance with Rule 10b5-1 on March 12, 2020 to satisfy the tax withholding obligations triggered by the vesting of RSUs, and does not represent a discretionary trade by the Reporting Person.

SEC source: 0001209191-21-014551 · doc4.xml · nonDerivative · entry 2

Terrillion Scott · CIK 0001706426 · Sec'y; Chief Compliance & G.C.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,432

F2 · kind: This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person in accordance with Rule 10b5-1 on September 6, 2018 to satisfy the tax withholding obligations triggered by the vesting of RSUs, and does not represent a discretionary trade by the Reporting Person.

SEC source: 0001209191-21-014549 · doc4.xml · nonDerivative · entry 2

Menzaghi Frederique Ph.D. · CIK 0001597152 · Chief Scientific Off,SVP-R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 112,677

F2 · kind: This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person in accordance with Rule 10b5-1 on September 6, 2018 to satisfy the tax withholding obligations triggered by the vesting of RSUs, and does not represent a discretionary trade by the Reporting Person.

SEC source: 0001209191-21-014547 · doc4.xml · nonDerivative · entry 1

CHALMERS DEREK T · CIK 0001166287 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 955,343

F1 · shares: Represents the number of shares that vested under a performance-based restricted stock unit award (the "RSU") based on the Issuer's satisfaction of certain performance criteria of the award. In light of the performance-based vesting conditions of the award, such shares were not reportable under Section 16 until vesting was determined, which occurred on February 23, 2021. The vested shares represents the last possible vesting event of the total number of shares subject to the award.

SEC source: 0001209191-21-014548 · doc4.xml · nonDerivative · entry 1

Goncalves Joana · CIK 0001756991 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,075

F1 · shares: Represents the number of shares that vested under a performance-based restricted stock unit award (the "RSU") based on the Issuer's satisfaction of certain performance criteria of the award. In light of the performance-based vesting conditions of the award, such shares were not reportable under Section 16 until vesting was determined, which occurred on February 23, 2021. The vested shares represents the last possible vesting event of the total number of shares subject to the award.

SEC source: 0001209191-21-014551 · doc4.xml · nonDerivative · entry 1

Terrillion Scott · CIK 0001706426 · Sec'y; Chief Compliance & G.C.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 48,436

F1 · shares: Represents the number of shares that vested under a performance-based restricted stock unit award (the "RSU") based on the Issuer's satisfaction of certain performance criteria of the award. In light of the performance-based vesting conditions of the award, such shares were not reportable under Section 16 until vesting was determined, which occurred on February 23, 2021. The vested shares represents the last possible vesting event of the total number of shares subject to the award.

SEC source: 0001209191-21-014549 · doc4.xml · nonDerivative · entry 1

Menzaghi Frederique Ph.D. · CIK 0001597152 · Chief Scientific Off,SVP-R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 117,680

F1 · shares: Represents the number of shares that vested under a performance-based restricted stock unit award (the "RSU") based on the Issuer's satisfaction of certain performance criteria of the award. In light of the performance-based vesting conditions of the award, such shares were not reportable under Section 16 until vesting was determined, which occurred on February 23, 2021. The vested shares represents the last possible vesting event of the total number of shares subject to the award.

SEC source: 0001209191-21-013877 · doc4.xml · nonDerivative · entry 1

Goncalves Joana · CIK 0001756991 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,075

F1 · kind: This sale was made pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person on November 15, 2019, and amended on August 19, 2020.

SEC source: 0001209191-21-005146 · doc4.xml · nonDerivative · entry 1

Goncalves Joana · CIK 0001756991 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,075

F1 · kind: This sale was made pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person on November 15, 2019, and amended on August 19, 2020.

SEC source: 0001209191-20-065578 · doc4.xml · nonDerivative · entry 1

CHALMERS DEREK T · CIK 0001166287 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 936,593

F1 · kind: This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person in accordance with Rule 10b5-1 on September 6, 2018 to satisfy the tax withholding obligations triggered by the vesting of the RSUs reported on Form 4 filed with the Securities and Exchange Commission on December 29, 2020, and does not represent a discretionary trade by the Reporting Person.

F2 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding as described in footnote (1).

SEC source: 0001209191-20-065579 · doc4.xml · nonDerivative · entry 1

Goncalves Joana · CIK 0001756991 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,075

F1 · kind: This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person in accordance with Rule 10b5-1 on March 12, 2020 to satisfy the tax withholding obligations triggered by the vesting of the RSUs reported on Form 4 filed with the Securities and Exchange Commission on December 29, 2020, and does not represent a discretionary trade by the Reporting Person.

F2 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding as described in footnote (1).

SEC source: 0001209191-20-065582 · doc4.xml · nonDerivative · entry 1

Terrillion Scott · CIK 0001706426 · Sec'y; Chief Compliance & G.C.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 42,436

F1 · kind: This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person in accordance with Rule 10b5-1 on September 6, 2018 to satisfy the tax withholding obligations triggered by the vesting of the RSUs reported on Form 4 filed with the Securities and Exchange Commission on December 29, 2020, and does not represent a discretionary trade by the Reporting Person.

F2 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding as described in footnote (1).

SEC source: 0001209191-20-065581 · doc4.xml · nonDerivative · entry 1

Menzaghi Frederique Ph.D. · CIK 0001597152 · Chief Scientific Off,SVP-R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 109,680

F1 · kind: This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person in accordance with Rule 10b5-1 on September 6, 2018 to satisfy the tax withholding obligations triggered by the vesting of the RSUs reported on Form 4 filed with the Securities and Exchange Commission on December 29, 2020, and does not represent a discretionary trade by the Reporting Person.

F2 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding as described in footnote (1).

SEC source: 0001209191-20-065406 · doc4.xml · nonDerivative · entry 2

CHALMERS DEREK T · CIK 0001166287 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 942,671

F2 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 13, 2020.

SEC source: 0001209191-20-065406 · doc4.xml · nonDerivative · entry 1

CHALMERS DEREK T · CIK 0001166287 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 947,671

F1 · shares: Represents the number of shares that vested under a performance-based restricted stock unit award (the "RSU") based on the Issuer's satisfaction of certain performance criteria of the award. In light of the performance-based vesting conditions of the award, such shares were not reportable under Section 16 until vesting was determined, which occurred on December 23, 2020. The vested shares represents the third of four possible vesting events of the total number of shares subject to the award. The remaining shares subject to the award will vest only upon the satisfaction of additional performance vesting criteria. Each RSU represents the contingent right to receive one share of common stock of the Issuer.

SEC source: 0001209191-20-065408 · doc4.xml · nonDerivative · entry 1

Goncalves Joana · CIK 0001756991 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,373

F1 · shares: Represents the number of shares that vested under a performance-based restricted stock unit award (the "RSU") based on the Issuer's satisfaction of certain performance criteria of the award. In light of the performance-based vesting conditions of the award, such shares were not reportable under Section 16 until vesting was determined, which occurred on December 23, 2020. The vested shares represents the third of four possible vesting events of the total number of shares subject to the award. The remaining shares subject to the award will vest only upon the satisfaction of additional performance vesting criteria. Each RSU represents the contingent right to receive one share of common stock of the Issuer.

SEC source: 0001209191-20-065409 · doc4.xml · nonDerivative · entry 1

Menzaghi Frederique Ph.D. · CIK 0001597152 · Chief Scientific Off,SVP-R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 112,492

F1 · shares: Represents the number of shares that vested under a performance-based restricted stock unit award (the "RSU") based on the Issuer's satisfaction of certain performance criteria of the award. In light of the performance-based vesting conditions of the award, such shares were not reportable under Section 16 until vesting was determined, which occurred on December 23, 2020. The vested shares represents the second of three possible vesting events of the total number of shares subject to the award. The remaining shares subject to the award will vest only upon the satisfaction of additional performance vesting criteria. Each RSU represents the contingent right to receive one share of common stock of the Issuer.

SEC source: 0001209191-20-065407 · doc4.xml · nonDerivative · entry 1

Terrillion Scott · CIK 0001706426 · Sec'y; Chief Compliance & G.C.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,382

F1 · shares: Represents the number of shares that vested under a performance-based restricted stock unit award (the "RSU") based on the Issuer's satisfaction of certain performance criteria of the award. In light of the performance-based vesting conditions of the award, such shares were not reportable under Section 16 until vesting was determined, which occurred on December 23, 2020. The vested shares represents the third of four possible vesting events of the total number of shares subject to the award. The remaining shares subject to the award will vest only upon the satisfaction of additional performance vesting criteria. Each RSU represents the contingent right to receive one share of common stock of the Issuer.

SEC source: 0001209191-20-065107 · doc4.xml · nonDerivative · entry 1

Goncalves Joana · CIK 0001756991 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,373

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 Trading Plan, as amended, adopted by the Reporting Person.

SEC source: 0001209191-20-064450 · doc4.xml · nonDerivative · entry 1

CHALMERS DEREK T · CIK 0001166287 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 928,921

SEC source: 0001209191-20-063097 · doc4.xml · nonDerivative · entry 1

CHALMERS DEREK T · CIK 0001166287 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 933,921

SEC source: 0001209191-20-060532 · doc4.xml · nonDerivative · entry 1

Goncalves Joana · CIK 0001756991 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,373

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 Trading Plan, as amended, adopted by the Reporting Person.

SEC source: 0001209191-20-060097 · doc4.xml · nonDerivative · entry 1

Posner Christopher · CIK 0001748265 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,200

SEC source: 0001209191-20-060096 · doc4.xml · nonDerivative · entry 1

Ives Jeffrey L. · CIK 0001614096 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,700

SEC source: 0001209191-20-060288 · doc4a.xml · nonDerivative · entry 1

Ives Jeffrey L. · CIK 0001614096 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,700

SEC source: 0001209191-20-059475 · doc4.xml · nonDerivative · entry 1

CHALMERS DEREK T · CIK 0001166287 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 941,421

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 13, 2020.

SEC source: 0001209191-20-059476 · doc4.xml · nonDerivative · entry 1

VOGELBAUM MARTIN · CIK 0001237624 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,400

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.07 - $16.11, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

SEC source: 0001209191-20-058353 · doc4.xml · nonDerivative · entry 1

Goncalves Joana · CIK 0001756991 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,373

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 Trading Plan, as amended, adopted by the Reporting Person.

SEC source: 0001209191-20-055597 · doc4.xml · nonDerivative · entry 1

Goncalves Joana · CIK 0001756991 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,373

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 Trading Plan, as amended, adopted by the Reporting Person.

SEC source: 0001209191-20-054142 · doc4.xml · derivative · entry 1

Reilly Thomas Charles · CIK 0001827590 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 175,000

Underlying: Common Stock · 175,000 shares

Expires 2030-10-01

F1 · derivative.exercise_date: 25% of the shares vest and become exercisable on October 1, 2021; the balance of the shares vest and become exercisable in a series of 36 successive equal monthly installments at the end of each calendar month thereafter, subject to the Reporting Person's continuous service with the Issuer as of each such date.

SEC source: 0001209191-20-049749 · doc4.xml · nonDerivative · entry 1

CHALMERS DEREK T · CIK 0001166287 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 953,220

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 13, 2020.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.00 to $16.02, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

SEC source: 0001209191-20-045254 · doc4.xml · nonDerivative · entry 1

CHALMERS DEREK T · CIK 0001166287 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 956,421

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 13, 2020.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.25 to $16.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

SEC source: 0001209191-20-040373 · doc4.xml · nonDerivative · entry 1

CHALMERS DEREK T · CIK 0001166287 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 961,421

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 13, 2020.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.01 to $17.26, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

SEC source: 0001209191-20-039488 · doc4.xml · derivative · entry 1

Shiff Susan Ph.D. · CIK 0001811463 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 38,000

Underlying: Common Stock · 38,000 shares

Expires 2030-06-26

F1 · derivative.exercise_date: The option shall vest and become exercisable in twelve (12) equal quarterly installments beginning on September 26, 2020 such that the option will be fully vested and exercisable on June 26, 2023, subject to the Reporting Person's continued service to the Issuer on each such date.

SEC source: 0001209191-20-036385 · doc4.xml · nonDerivative · entry 2

Goncalves Joana · CIK 0001756991 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,373

F2 · kind: This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person in accordance with Rule 10b5-1 on March 12, 2020 to satisfy the tax withholding obligations triggered by the vesting and of the RSUs reported herein as described in greater detail in footnote (1), and does not represent a discretionary trade by the Reporting Person.

F3 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding as described in footnote (2).

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.09 to $15.35, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (4) to this Form 4.

SEC source: 0001209191-20-036385 · doc4.xml · nonDerivative · entry 1

Goncalves Joana · CIK 0001756991 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,000

F1 · shares: Represents the number of shares that vested under a performance-based restricted stock unit award (the "RSU") based on the Issuer's satisfaction of certain performance criteria of the award. In light of the performance-based vesting conditions of the award, such shares were not reportable under Section 16 until vesting was determined, which occurred on June 10, 2020. Each RSU represents the contingent right to receive one share of common stock of the Issuer.

SEC source: 0001209191-20-035071 · doc4.xml · derivative · entry 2

VOGELBAUM MARTIN · CIK 0001237624 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,600

Underlying: Common Stock · 21,600 shares

Expires 2030-06-04

F2 · derivative.exercise_date: This option was granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. The shares underlying the option vest and become exercisable on the earlier of (i) June 4, 2021 and (ii) immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date.

SEC source: 0001209191-20-035071 · doc4.xml · nonDerivative · entry 1

VOGELBAUM MARTIN · CIK 0001237624 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,400

F1 · shares: Represents the number of shares underlying restricted stock units ("RSUs") granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest on the earlier of (i) June 4, 2021 and (ii) immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date.

SEC source: 0001209191-20-035067 · doc4.xml · derivative · entry 2

BAINS HARRISON M JR · CIK 0001202282 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,800

Underlying: Common Stock · 10,800 shares

Expires 2030-06-04

F2 · derivative.exercise_date: This option was granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. The shares underlying the option vest and become exercisable on the earlier of (i) June 4, 2021 and (ii) immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date.

SEC source: 0001209191-20-035067 · doc4.xml · nonDerivative · entry 1

BAINS HARRISON M JR · CIK 0001202282 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,200

F1 · shares: Represents the number of shares underlying restricted stock units ("RSUs") granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest on the earlier of (i) June 4, 2021 and (ii) immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date.

SEC source: 0001209191-20-035065 · doc4.xml · derivative · entry 2

Ives Jeffrey L. · CIK 0001614096 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,800

Underlying: Common Stock · 10,800 shares

Expires 2030-06-04

F2 · derivative.exercise_date: This option was granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. The shares underlying the option vest and become exercisable on the earlier of (i) June 4, 2021 and (ii) immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date.

SEC source: 0001209191-20-035065 · doc4.xml · nonDerivative · entry 1

Ives Jeffrey L. · CIK 0001614096 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,200

F1 · shares: Represents the number of shares underlying restricted stock units ("RSUs") granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest on the earlier of (i) June 4, 2021 and (ii) immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date.

SEC source: 0001209191-20-035060 · doc4.xml · derivative · entry 2

Posner Christopher · CIK 0001748265 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,800

Underlying: Common Stock · 10,800 shares

Expires 2030-06-04

F2 · derivative.exercise_date: This option was granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. The shares underlying the option vest and become exercisable on the earlier of (i) June 4, 2021 and (ii) immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date.